Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

Tile scans were acquired using a voxel size of 0.332x0.332x1.200 µm, a pixel dwell of 2µs, and a 10% tile overlap. For 3D visualization, shift correction, object rendering, and cell tracking, ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

POLK expression in neurons and report an important observation that POLK exhibits an age-dependent change in subcellular localization, from the nucleus in young tissue to the cytoplasm in old tissue.

The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics) for the treatment of relapsed or refractory adult B-cell acute lymphoblastic ...

An 81-year-old woman with a 2-day history of vomiting and abdominal distension attended our hospital. The patient reported no fever, recent travel abroad, or change of bowel habit. She had a 3-year ...

Clinical Data shows that Q-1802 has significant anti-tumor activity.

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks after the completion of radiation, consisting of ...

Aumolertinib showed improved PFS in NSCLC and ivonescimab outperforms pembrolizumab in advanced cases. Plus, insights into CAR T-cell therapy and its associated AEs are discussed in relapsed multiple ...